This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech

A Battle Rages Over Whether an Old Drug Can Be New Again

A Battle Rages Over Whether an Old Drug Can Be New Again

  • Tickers in this article:
  • UTHR
  • NVS

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder.

02/27/15 - 01:58 PM EST

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss

  • Tickers in this article:
  • HZNP

Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.

02/27/15 - 10:31 AM EST

FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market

FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market

BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.

02/27/15 - 06:30 AM EST

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss

  • Tickers in this article:
  • HZNP

Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.

02/27/15 - 10:31 AM EST

GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

  • Tickers in this article:
  • GSK

GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores.

02/25/15 - 09:48 AM EST

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.

02/25/15 - 11:47 AM EST

Vanguard Health Care ETF Still in Good Shape Says Stadion Manager

Vanguard Health Care ETF Still in Good Shape Says Stadion Manager

The Vanguard Health Care ETF (VHT) will continue its terrific run because it employs a healthy mix of big-cap pharma and biotech.

02/24/15 - 10:35 AM EST

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

  • Tickers in this article:
  • VRTX

Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.

02/23/15 - 11:06 AM EST

Valeant Pharmaceuticals to Acquire Salix Pharma for $14.5 Billion

Valeant Pharmaceuticals to Acquire Salix Pharma for $14.5 Billion

Laval, Canada-based Valeant Pharmaceuticals announced on Sunday that it would acquire Raleigh, North Carolina-based Salix Pharmaceuticals for an enterprise value of $14.5 billion.

02/23/15 - 02:31 PM EST

Valent & Salix, 3M & Polypore Deals Can't Stop Stocks From Slipping

Valent & Salix, 3M & Polypore Deals Can't Stop Stocks From Slipping

U.S. stocks slipped on Wall Street but werestill near record highs at Monday's midday trading.

02/23/15 - 11:47 AM EST

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.

02/23/15 - 11:14 AM EST

Celgene (CELG) Stock Gained Today on European Commission Approval of Revlimid

Celgene (CELG) Stock Gained Today on European Commission Approval of Revlimid

  • Tickers in this article:
  • CELG

Celgene (CELG) shares closed trading up after the company had its Revilmid treatment approved by the European Commission.

02/20/15 - 05:01 PM EST

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

02/20/15 - 03:47 PM EST

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

  • Tickers in this article:
  • ARIA

Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.

02/20/15 - 07:09 AM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs